PharmaNet Pursues Strategic Alternatives, Possible Sale

Friday, December 19, 2008 11:57 AM

Troubled contract research organization (CRO) PharmaNet Development Group announced Thursday that it is working with a financial advisor from USB Investment Bank to explore strategic alternatives, including the potential sale of the company.

This move follows a year of struggles for the Princeton, N.J.-based CRO. Since the start of 2008, PharmaNet’s share price has plunged 97% from $39.19 in January to $1.01 in early morning trading Friday, and, in September, PharmaNet cut its full-year revenue forecast more than $30 million.

“The board of directors and management believe that pursuing strategic alternatives will maximize shareholder value,” said PharmaNet president and CEO Jeffrey McMullen in a company statement.

The CRO has received a several non-binding letters of interest regarding the sale of the company from non-competitors, according to the company release, but the company will not comment further on the process until a definitive strategic decision or agreement is made.

Share:          
CWWeekly

April 20

Christie Clinic, PMG Research's 12th clinical research site, expands its geographic reach north to Illinois

Clinipace acquires Accovion to expand European presence, following an infusion of equity that could lead to more deals

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs